South Korea requests Gilead to supply remdesivir to treat over 5,000 COVID patients
SEOUL (SOUTH KOREA) – Bracing for a potential second wave of infections, South Korea has asked Gilead Sciences Inc to supply enough vials of its anti-viral drug remdesivir to treat more than 5,000 COVID-19 patients, said a lawmaker on Wednesday.
The drug is in high demand as it has shown promising results in altering the course of COVID-19. But there are concerns about its availability after Gilead allocated most of its stocks to the United States over the next three months.
Seoul authorities said last week that there are 33 critically ill people who need the drug, which helps to shorten hospital recovery time as shown in clinical trials.
South Korea sent a letter to the pharmaceutical company on June 3 requesting doses for 360 patients who urgently need the drug and enough stocks to treat 5,000 more if there is a second wave.
The contents of the letter were disclosed on Wednesday by lawmaker Kang Gi-yun.
(Photos syndicated via Reuters)
This story has been edited by BH staff and is published from a syndicated field